PF-05212384 (PKI-587)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PF-05212384 (PKI-587), covering 2025-09-08 to 2025-09-08. Get the full timeline:
Most recent: Clinical Trial Update: PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK) [Phase 2]